Study ID: AstraZeneca_EUCLID_D5135C00001
Description:

A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Location:
Fargo Region
Principal Investigator:
Thomas Haldis D.O.
Disease:
Stage:
N/A

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list